The National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, has partnered with AstraZeneca India to strengthen clinical trial capabilities at 25 research sites outside India’s major metropolitan centres. The initiative aims to train clinical research professionals, improve site readiness and expand India’s participation in global clinical trials.
However, the partnership announcement offers few details on how quickly the programme will be implemented, how much funding it will receive or what measurable outcomes the selected sites are expected to deliver. Those details will matter in determining whether the initiative can translate its ambitions into a stronger clinical research network.
The memorandum of understanding was signed in New Delhi in the presence of Manoj Joshi, Secretary of the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers. The collaboration is aligned with the government’s Biopharma SHAKTI initiative, which aims to establish 1,000 clinical trial sites across India.
The initial programme will focus on 25 sites, assessing their capabilities and providing training, mentoring and support for documentation, ethics, safety and trial feasibility. The announcement does not specify the locations of the selected sites, the criteria for choosing them or when the assessments and training are expected to be completed.
25-Site Pilot Faces Questions on Execution and Accountability
The partnership seeks to address a longstanding challenge in clinical research: building the skilled workforce and institutional capacity required to conduct trials beyond established research centres in major cities.
AstraZeneca India will contribute clinical development expertise, engage Indian and international specialists, and support training, workshops, governance and readiness assessments. NIPER Raebareli will provide an academic platform for structured training and certification through a proposed Centre of Excellence.
The government is expected to provide guidance and endorsement to align the programme with national research priorities. But the announcement does not spell out the respective financial commitments of the government, NIPER and AstraZeneca, or identify who will be responsible for monitoring the programme’s progress.
Nor does it set out specific targets for the number of professionals to be trained, the number of sites expected to become trial-ready or the time required to meet that standard. Without publicly defined benchmarks, it will be difficult to assess the programme’s effectiveness or compare the performance of participating sites.
Readiness assessments will also need to translate into practical improvements in areas such as research staffing, ethics committee processes, patient protection, data quality and regulatory compliance. Training alone cannot ensure that a site is equipped to run complex trials consistently.
The partnership could help expand research opportunities beyond metropolitan centres, but its impact will depend on how these operational challenges are addressed.
Biopharma SHAKTI’s Wider Ambition Depends on Results
The government has positioned Biopharma SHAKTI as part of a broader effort to strengthen India’s biopharmaceutical research and development ecosystem. Its target of 1,000 clinical trial sites reflects an ambition to build capacity beyond the country’s established research centres.
The NIPER-AstraZeneca collaboration is intended to provide a model that could eventually be replicated in additional locations and therapeutic areas. The ministry has indicated that the approach could extend beyond oncology after a successful proof-of-concept phase, although the announcement does not specify how that success will be measured.
NIPER Raebareli Director Shubhini Saraf said the proposed Centre of Excellence would provide a dedicated platform for structured training and certification in clinical research. The institute aims to combine academic and industry expertise to develop a skilled workforce and create a model that could be adapted elsewhere.
Praveen Rao Akkinepally, Country President and Managing Director of AstraZeneca Pharma India, said clinical research was essential to delivering innovative medicines and that the collaboration aimed to strengthen India’s research capacity and participation in global trials.
Expanding the number of trial sites could create opportunities for patients outside major cities to participate in clinical research and help researchers reach more diverse populations. Those benefits, however, depend on whether the sites become operational, recruit eligible participants and maintain robust ethical and scientific standards.
The immediate test for the partnership will be whether the 25 sites move beyond assessments and training to demonstrate sustained trial readiness. Clear timelines, transparent selection criteria, measurable performance indicators and regular reporting would help establish whether the initiative can deliver on its broader promise.
Until those details emerge, the agreement represents a plan to strengthen India’s clinical research infrastructure rather than evidence that the country’s capacity for conducting trials has already expanded.
Arun Kumar N